European Psychiatry - Volume 33 - March 2016

526 / 812

S522 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
EV539
Plasma concentrations of
endocannabinoids and congeners in a
primary care sample of depressed
patients: Influence of biological
variables, severity and antidepressant
medication
P. Romero-Sanchiz ∗, R. Nogueira-Arjona , F. Mayoral-Cleríes ,
F. Rivas-Guerrero , P. Araos-Gómez , M. Pedraz-Fernández ,
A. Serrano-Criado , F.J. Pavón-Morón , R. De la Torre-Fornell ,
A. Pastor-Bosch , F. Rodríguez de Fonseca
1 IBIMA – Hospital Regional Universitary Malaga, Mental Health,
Málaga, Spain
2 IBIMA – University of Malaga, Personality – assessment and
psychological treatment, Málaga, Spain
3 IBIMA, Neropsychopharmacology, Malaga, Spain
4 IMIM, Integrated Pharmacology and Systems Neurosciences,
Barcelona, Spain
∗ Corresponding author.
Introduction Endocannabinoid system has been highlighted as
one of the most relevant research topics by neurobiologists, phar-
macists, basic scientists and clinicians. The association between
endocannabinoids and its congeners and mood disorders is rela-
tively recent. However, evidence from both clinical and preclinical
studies is increasing and many researchers point out endocannabi-
noid system and particularly endocannabinoids and congeners as
promising pharmacological targets.
Aims and objectives Themain objective of this study is to compare
the plasma concentrations of endocannabinoids and congeners
between a sample of patients with depression and a sample of con-
trol subjects, and the influence of variables such as age, body mass
index, gender, severity of symptoms, and antidepressant medica-
tion.
Method Plasma concentrations of endocannabinoids and con-
geners will be analyzed in 69 patients with depression from
primary care and 47 controls using mass spectrometry analysis.
Results Statistically significant differences in 2-
arachidonoylglycerol and monoacylglycerols were found between
both samples. Somatic symptoms of depression seems to be more
related to these compounds that to cognitive-affective symptoms.
In addition, differences between mildly and moderately depressed
patients were found in concentrations of AEA, LEA, DGLEA and
POEA. Patients with antidepressant medication showed higher
levels of 2-AG, DGLEA and OEA.
Conclusions The results of this study provide evidence support-
ing the hypothesis that in depression there is a dysregulation of the
inflammatory signaling and, consequently the immune system. The
results of this study could also support the realization of transla-
tional research to better understand the mechanisms of this widely
distributed system.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV540
Efficacy of lurasidone in major
depression with mixed features:
Pattern of improvement in depressive
and manic symptoms
A.A. Nierenberg sai ∗ ao Pikalov uppes
A. Loebel
1 Boston, USA
2 Sunovion Pharmaceuticals Inc., Medical Affairs, Marlborough, USA
3 Sunovion Pharmaceuticals Inc., Biostatisticsd, Fort Lee, USA
4 Sunovion Pharmaceuticals Inc., Medical Affairs, Fort Lee, USA
5 Stanford School of Medicine, Psychiatry and Behavioral Sciences,
Stanford, USA
∗ Corresponding author.
Introduction Evidence indicates that manic symptoms, below the
threshold for hypomania (mixed features), are common in individ-
uals with major depressive disorder (MDD).
Objectives/aims To evaluate the effect of lurasidone on specific
depressive and manic symptoms, based on Montgomery Asberg
Depression Rating Scale (MADRS) and Young Mania Rating Scale
(YMRS) items, in patients with MDD with mixed features.
Methods Patients meeting DSM-IV-TR criteria for MDD, who
presented with 2–3 protocol-specified manic symptoms, were ran-
domized to 6 weeks of double-blind treatment with lurasidone
monotherapy 20–60mg/d (n = 109) or placebo (n = 100). Change
from baseline in the MADRS total, MADRS-6 core depression sub-
scale, individual MADRS items, and total and individual items of
the YMRS were analyzed by MMRM, and Cohen’s d effect sizes (d)
were calculated for week 6 change scores.
Results Lurasidone improved depressive symptoms at week 6
in the MADRS total score (–20.5 vs. –13.0; P < 0.0001; d = 0.8) and
MADRS-6 core depression score (–13.0 vs. –8.5; P < 0.0001; d = 0.7).
Significant improvement on lurasidone was observed at week 6 on
all ten MADRS items (d = 0.36–0.78). Effect sizes for the MADRS-
6 core depression subscale items ranged from 0.36 to 0.78 at
week 6. Treatment with lurasidone was associated with signifi-
cantly greater week 6 improvement on the YMRS (–7.0 vs. –4.9;
P < 0.0001). Effect sizes for the 5 YMRS items with baseline item
severity ≥ 2 ranged from 0.32 to 0.48.
Conclusions In this study of MDD with mixed features, lurasi-
done was effective in treating the range of depressive and manic
symptoms that patients presented with.
Sponsored by Sunovion Pharmaceuticals Inc.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV541
Effect of meta-cognitive therapy on
patients of depression: A case series
from India
V. Sharma ∗, M. Mehta , R. Sagar
1 New Delhi, India
2 All India Institute of Medical Sciences, Department of Psychiatry,
New Delhi, India
∗ Corresponding author.
Background Metacognitive Therapy (MCT) for depression aims
at targeting attentional control, rumination, worry, and metacog-
nitive beliefs of individuals.
Aim The purpose of this study was to examine the effects of
meta-cognitive therapy (MCT) in the treatment of patients with
a diagnosis of major depressive disorder.
Methods Five patients diagnosed as having major depressive
disorder were recruited for the study. Each patient received 10 ses-
sions of MCT up to 1 hour each at a frequency of once per week.
All patients were assessed at baseline, which was followed by 10
weekly sessions of MCT with post-intervention assessment and
follow-up assessments at 1-month post-treatment. Primary out-
come measures were the reduction in symptoms of depression,
worry, and rumination. Outcomes were assessed via self-report
using structured psychological tests.
Data analysis Datawas analyzedusing individual frequency com-
parisons where measures of differences were obtained within
each phase of assessment. Pre-intervention, post-intervention and
follow-up measures were compared along with identification of
within phase differences. Meticulous analysis was also performed
using measures of qualitative analysis. For this purpose, following
measures were used: homework assignment analysis, within ses-